RightFit
Not yet recruitingPhase not listed

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
No age limits stated
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Time periods mentioned: 15 years

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "The LTFU study is a study intended to characterize long-term safety for 15 years post-ARD103 administration."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study checks the long-term safety of ARD103 CAR-T cell therapies. It is for people with AML or MDS who received these therapies in the earlier study.

This study will evaluate the long-term safety of ARD103 cellular therapies

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • You have AML (a blood and bone marrow cancer) or MDS (a disease that affects how blood cells are made) that came back or did not respond to treatment.
  • You received ARD103 CAR-T cell therapies in the earlier study.
  • You can understand and follow the study steps and have signed a form agreeing to take part.

Who can't join

    Simplified for readability. The official criteria below are what the study team uses.

    Official eligibility criteria

    Inclusion Criteria: * The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study. * The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document. Exclusion Criteria: * There are no specific exclusion criteria for this study

    Study sites (3)

    NC

    TX